Human iPS cell–derived alveolar epithelium repopulates lung extracellular matrix
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The use of induced pluripotent stem cells (iPSCs) has been postulated to be the most effective strategy for developing patient-specific respiratory epithelial cells, which may be valuable for lung-related cell therapy and lung tissue engineering. We generated a relatively homogeneous population of alveolar epithelial type II (AETII) and type I (AETI) cells from human iPSCs that had phenotypic properties similar to those of mature human AETII and AETI cells. We used these cells to explore whether lung tissue can be regenerated in vitro. Consistent with an AETII phenotype, we found that up to 97% of cells were positive for surfactant protein C, 95% for mucin-1, 93% for surfactant protein B, and 89% for the epithelial marker CD54. Additionally, exposing induced AETII to a Wnt/β-catenin inhibitor (IWR-1) changed the iPSC-AETII-like phenotype to a predominantly AETI-like phenotype. We found that of induced AET1 cells, more than 90% were positive for type I markers, T1α, and caveolin-1. Acellular lung matrices were prepared from whole rat or human adult lungs treated with decellularization reagents, followed by seeding these matrices with alveolar cells derived from human iPSCs. Under appropriate culture conditions, these progenitor cells adhered to and proliferated within the 3D lung tissue scaffold and displayed markers of differentiated pulmonary epithelium.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Engineered whole organs and complex tissues
Badylak, S. F., Weiss, D. J., Caplan, A., & Macchiarini, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60073-7 · Cited by 417
RetractedInduction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310 · cited 2×
“Given that iPSCs can be derived from the patient to be treated, they could provide a cell source that is genetically identical to the patient, allowing tissue generated from these cells to avoid immune rejection (9, 12).”
Regeneration and orthotopic transplantation of a bioartificial lung
Ott, H. C., Clippinger, B., Conrad, C., Schuetz, C., Pomerantseva, I., Ikonomou, L., Kotton, D., & Vacanti, J. P. (2010) · Nature Medicine · doi:10.1038/nm.2193 · Cited by 1,090
Alveolar epithelial type II cell: defender of the alveolus revisited
Fehrenbach, H. (2001) · Respiratory Research · doi:10.1186/rr36 · Cited by 757 · cited 1×
“When damage occurs to the ATI pneumocytes, ATII cells proliferate and can, in turn, differentiate into ATI cells (29, 30, 32).”
Acellular Normal and Fibrotic Human Lung Matrices as a Culture System for In Vitro Investigation
Booth, A. J., Hadley, R., Cornett, A. M., Dreffs, A. A., Matthes, S. A., Tsui, J. L., Weiss, K., Horowitz, J. C., Fiore, V. F., Barker, T. H., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0754oc · Cited by 665 · cited 10×
“For immunostaining, cells were washed with PBS, fixed in 4% para-formaldehyde for 20 minutes at room temperature (RT) and permeabilized with 0.1% Triton X-100 in PBS for 15 minutes at RT. Cells were blocked in 3% BSA in PBS for 60 minutes at RT and incubated with primary antibody overnight at 4°C.”
InfluentialSelf-citationInduction and monitoring of definitive and visceral endoderm differentiation of mouse ES cells
Yasunaga, M., Tada, S., Torikai-Nishikawa, S., Nakano, Y., Okada, M., Jakt, L. M., Nishikawa, S., Chiba, T., Era, T., & Nishikawa, S.-I. (2005) · Nature Biotechnology · doi:10.1038/nbt1167 · Cited by 471
Efficient Derivation of Purified Lung and Thyroid Progenitors from Embryonic Stem Cells
Longmire, T. A., Ikonomou, L., Hawkins, F., Christodoulou, C., Cao, Y., Jean, J. C., Kwok, L. W., Mou, H., Rajagopal, J., Shen, S. S., et al. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.01.019 · Cited by 384
Lung Transplantation in the United States, 1998–2007
McCurry, K. R., Shearon, T. H., Edwards, L. B., Chan, K. M., Sweet, S. C., Valapour, M., Yusen, R., & Murray, S. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02569.x · Cited by 113 · cited 1×
“As a result, many patients die each year while on a waiting list or because of transplant complications (1, 3, 4).”
Cited by
Hogan, B. L. M., Barkauskas, C. E., Chapman, H. A., Epstein, J. A., Jain, R., Hsia, C. C. W., Niklason, L., Calle, E., Le, A., Randell, S. H., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.07.012 · Cited by 876
“…anterior foregut and lung development is critical for deriving lung endoderm progenitors from mouse and human PSCs. Key pathways include those downstream of activin/nodal, Wnts, Bmps, and Fgfs (Ghaedi et al., 2013; Huang et al., 2014; Longmire et al., 2012; Mou et al., 2012; Wong et al., 2012).”
BackgroundSelf-citationIn vitro generation of human pluripotent stem cell derived lung organoids
Dye, B. R., Hill, D. R., Ferguson, M. A., Tsai, Y.-H., Nagy, M. S., Dyal, R., Wells, J. M., Mayhew, C. N., Nattiv, R., Klein, O. D., et al. (2015) · eLife · doi:10.7554/elife.05098 · Cited by 819
Self-citationDiscovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Riva, L., Yuan, S., Yin, X., Martin-Sancho, L., Matsunaga, N., Pache, L., Burgstaller-Muehlbacher, S., De Jesus, P. D., Teriete, P., Hull, M. V., et al. (2020) · Nature · doi:10.1038/s41586-020-2577-1 · Cited by 760
Lung regeneration: mechanisms, applications and emerging stem cell populations
Kotton, D. N., & Morrisey, E. E. (2014) · Nature Medicine · doi:10.1038/nm.3642 · Cited by 515
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
White, K. M., Rosales, R., Yildiz, S., Kehrer, T., Miorin, L., Moreno, E., Jangra, S., Uccellini, M. B., Rathnasinghe, R., Coughlan, L., et al. (2021) · Science · doi:10.1126/science.abf4058 · Cited by 343
Meiners, S., Eickelberg, O., & Königshoff, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00186914 · Cited by 340
Decellularized matrices in regenerative medicine
Taylor, D. A., Sampaio, L. C., Ferdous, Z., Gobin, A. S., & Taite, L. J. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.04.044 · Cited by 337
Gotoh, S., Ito, I., Nagasaki, T., Yamamoto, Y., Konishi, S., Korogi, Y., Matsumoto, H., Muro, S., Hirai, T., Funato, M., et al. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.07.005 · Cited by 325
Porzionato, A., Stocco, E., Barbon, S., Grandi, F., Macchi, V., & De Caro, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124117 · Cited by 319
Multi-lineage human iPSC-derived platforms for disease modeling and drug discovery
Sharma, A., Sances, S., Workman, M. J., & Svendsen, C. N. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.02.011 · Cited by 296
“Organ decellularization can generate a natural collagenous scaffold upon which hiPSC-derivatives can be introduced, and this process has been particularly useful for generating biomechanically appropriate, but delicate scaffolds for lung tissue engineering (Ghaedi et al., 2013; Ghaedi et al., 2018; Gilpin et al., 2014…”
BackgroundMarx, U. (2016) · ALTEX · doi:10.14573/altex.1603161 · Cited by 295
“, 2016), lung (Ghaedi et al., 2013), gallbladder (Kauffman et al.”
Long-term expansion of alveolar stem cells derived from human iPS cells in organoids
Yamamoto, Y., Gotoh, S., Korogi, Y., Seki, M., Konishi, S., Ikeo, S., Sone, N., Nagasaki, T., Matsumoto, H., Muro, S., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4448 · Cited by 270
Current status of pluripotent stem cells: moving the first therapies to the clinic
Kimbrel, E. A., & Lanza, R. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4738 · Cited by 261
The genetic basis of idiopathic pulmonary fibrosis
Kropski, J. A., Blackwell, T. S., & Loyd, J. E. (2015) · European Respiratory Journal · doi:10.1183/09031936.00163814 · Cited by 193
Human airway organoid engineering as a step toward lung regeneration and disease modeling
Tan, Q., Choi, K. M., Sicard, D., & Tschumperlin, D. J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.10.046 · Cited by 191
Decellularized Extracellular Matrix for Remodeling Bioengineering Organoid's Microenvironment
Zhu, L., Yuhan, J., Yu, H., Zhang, B., Huang, K., & Zhu, L. (2023) · Small · doi:10.1002/smll.202207752 · Cited by 123
Park, K.-M., Hussein, K. H., Hong, S.-H., Ahn, C., Yang, S.-R., Park, S.-M., Kweon, O.-K., Kim, B.-M., & Woo, H.-M. (2016) · Tissue Engineering Part A · doi:10.1089/ten.tea.2015.0313 · Cited by 113
Shojaie, S., Ermini, L., Ackerley, C., Wang, J., Chin, S., Yeganeh, B., Bilodeau, M., Sambi, M., Rogers, I., Rossant, J., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.01.004 · Cited by 102
Stem cell-based therapy for pulmonary fibrosis
Cheng, W., Zeng, Y., & Wang, D. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03181-8 · Cited by 65
The long and winding road: stem cells for cystic fibrosis
Conese, M., Beccia, E., Castellani, S., Di Gioia, S., Colombo, C., Angiolillo, A., & Carbone, A. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1413087 · Cited by 15
Metadata
- Authors
- Ghaedi, M., Calle, E. A., Mendez, J. J., Gard, A. L., Balestrini, J., Booth, A., Bove, P. F., Gui, L., White, E. S., & Niklason, L. E.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-10-25
- Volume
- 123
- Issue
- 11
- Pages
- 4950-4962
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1976323116
- Cited by
- 230
- References
- 9
- FWCI
- 25.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.